Chengdu Shibeikang Biopharmaceutical Technology Co., Ltd.,

2026 年 5 月，成都施贝康生物医药科技有限公司受邀参加由美国心脏协会（AHA）主办的Vascular Discovery 2026 科学会议，以及由美国心血管研究卓越学会（ACRE）主办的2026 ACRE 血管研讨会。与来自全球的心血管领域专家学者、临床医生及产业界代表展开学术交流，并在 ACRE 研讨会上发表主题演讲，分享公司核心管线研发进展。 参与国际医学盛会，依托权威学术平台开展交流 Vascular Discovery 2026 科学会议：由美国心脏协会（AHA）主办，聚焦血管疾病从基础研究、转化医学到临床实践的全链条前沿进展，是全球血管生物学、抗栓治疗、外周血管疾病领域的顶级学术会议。 2026 ACRE 血管研讨会：由美国心血管研究卓越学会（ACRE）主办，聚焦血管疾病领域前沿科研成果互通与产学研协同创新，是北美乃至全球心血管领域的专业交流平台。 分享核心研发成果，展示创新管线与技术体系 在 2026 ACRE 血管研讨会上，施贝康市场医学部负责人发表题为《Shibeikang's Current R&D Pipeline: Key Candidates and Development Status》的主题演讲，系统介绍了公司的研发布局与核心管线研发进展： 重点分享了新一代抗血小板药物sbk002（吡康格雷）的研发进展，阐述了其针对性解决临床常见的氯吡格雷抵抗难题的创新价值，以及在安全性、有效性方面的差异化优势。 同时介绍了公司基于AI 代谢差异化研究平台打造的创新研发体系，以及从靶点发现、临床前研究到临床转化的全链条解决方案。演讲内容获得与会专家的高度关注。 成都施贝康生物医药科技有限公司，成立于2015年，是一家立足中国，面向全球，专注于新药差异化创新的研发性企业。施贝康秉承“施予众生、倍佑安康”的使命，坚持“以‘人’为本，革新为主，创新至上”的价值观。以临床需求为导向，坚持创新驱动发展，重点聚焦心脑血管、呼吸系统等疾病治疗领域，致力于成为全球一流的新药差异化创新的领导者，研发更好的新药，施予众生，加倍呵护人类健康。 详情请访问公司网站： https://www.sbkswyy.cn/ Shibeikang Presented at Vascular Discovery (AHA) and ACRE Vascular Symposium, Sharing Updates on its Pipeline Progress In May 2026, Chengdu Shibeikang Biomedical Technology Co., Ltd. was invited to participate in the Vascular Discovery 2026 Scientific Sessions organized by the American Heart Association (AHA) and the 2026 ACRE Vascular Symposium organized by the Academy of Cardiovascular Research Excellence (ACRE). The company engaged in academic exchanges with leading cardiovascular experts, clinicians, and industry representatives from around the world, and delivered a keynote address at the ACRE Symposium to share the progress of its core pipeline development. Engaging with Premier International Medical Conferences Through Authoritative Academic Platforms The Vascular Discovery 2026 Scientific Sessions, organized by the AHA, focus on cutting‑edge advances across the entire spectrum of vascular disease—from fundamental research and translational medicine to clinical practice. It is a top‑tier international conference in vascular biology, antithrombotic therapy, and peripheral vascular disease. The 2026 ACRE Vascular Symposium, organized by the Academy of Cardiovascular Research Excellence (ACRE), concentrates on the exchange of frontier research findings in vascular diseases and fosters collaborative innovation between academia and industry. It serves as a key professional exchange platform in the cardiovascular field in North America and globally. Presenting Core R&D Achievements and Showcasing the Innovative Pipeline and Technology Platform At the 2026 ACRE Vascular Symposium, the Head of the Medical Marketing at Shibeikang delivered a keynote address titled Shibeikang's Current R&D Pipeline: Key Candidates and Development Status, providing a systematic overview of the company’s R&D landscape and the progress of its core pipeline: The presentation highlighted the development progress of the next-generation antiplatelet agent sbk002 (Becondogrel), detailing its innovative value in addressing the common clinical challenge of clopidogrel resistance, as well as its differentiated advantages in safety and efficacy. In addition, the presentation also outlined the company's innovative R&D system built on an AI‑powered metabolically differentiated R&D platform, along with an end‑to‑end solution covering target discovery, preclinical research, and clinical translation. The presentation drew significant attention from the attending experts. Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment. For further details, please visit the official SBK website： https://www.sbkswyy.cn/

2026 年 5 月 13 日，由成都施贝康生物医药科技有限公司（下称“施贝康”）自主研发的口服小分子 PCSK9 抑制剂 S016 临床前研究成果，正式入选 2026 年欧洲心脏病学会年会，本次入选研究题目为《Preclinical Study and Evaluation of S016, a Novel Oral Small-Molecule PCSK9 Inhibitor》，相关内容将在大会期间展示并进行演讲汇报，与参会专家开展面对面学术交流。 图片来源：ESC Congress 2026 官网 ESC年会汇聚全球心血管前沿研发力量 欧洲心脏病学会年会是全球心血管领域极具影响力的顶级学术会议。本届大会定于 8 月 28 日 - 31 日在德国慕尼黑举办，汇聚全球超 3 万名心血管专家、学者及研发人员，聚焦前沿诊疗技术与创新药物研发进展。是全球心血管领域核心学术交流平台。 S016：创新布局直击临床痛点，具备高转化应用价值 当前降脂临床仍有明显短板：他汀类药物疗效有限，存在耐药及不良反应；现有 PCSK9 抑制剂均为注射剂，依从性差、费用偏高，不适用于 ASCVD 长期慢病管理。S016 为全新口服小分子 PCSK9 抑制剂，可精准靶向作用靶点、调控胆固醇清除通路。经临床前研究验证，药物降脂活性强、心脏安全性良好，叠加口服便捷性优势，可弥补现有治疗短板，填补口服 PCSK9 抑制剂临床空白，为高胆固醇血症及心血管疾病患者提供全新治疗方案，具备扎实的临床转化价值与产业发展前景。 成都施贝康生物医药科技有限公司，成立于2015年，是一家立足中国，面向全球，专注于新药差异化创新的研发性企业。施贝康秉承“施予众生、倍佑安康”的使命，坚持“以‘人’为本，革新为主，创新至上”的价值观。以临床需求为导向，坚持创新驱动发展，重点聚焦心脑血管、呼吸系统等疾病治疗领域，致力于成为全球一流的新药差异化创新的领导者，研发更好的新药，施予众生，加倍呵护人类健康。 详情请访问公司网站： https://www.sbkswyy.cn/ ESC Congress 2026 | Shibeikang Announces Study Findings of S016 Accepted for Presentation at European Society of Cardiology Congress 2026 On May 13, 2026, the preclinical study results of S016, an oral small-molecule PCSK9 inhibitor independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd. (hereinafter referred to as "Shibeikang"), have been officially accepted for presentation at the European Society of Cardiology Congress 2026. The accepted study is entitled "Preclinical Study and Evaluation of S016, a Novel Oral Small-Molecule PCSK9 Inhibitor." The findings will be presented during the congress, and Shibeikang will deliver an oral presentation and engage in face-to-face academic exchanges with experts attending the conference. ESC Congress Brings Together Global Cardiovascular Frontline Research and Development Capabilities The European Society of Cardiology Congress is a highly influential top-tier academic conference in the global cardiovascular field. The 2026 congress will be held in Munich, Germany, from August 28 to 31, bringing together over 30,000 cardiovascular experts, scholars, and researchers from around the world to focus on cutting-edge diagnostic and therapeutic technologies and advances in innovative drug development. It serves as a core academic exchange platform in the global cardiovascular field. S016: Innovative Approach Addressing Clinical Gaps with High Translational Value Current lipid-lowering therapies face notable limitations: statins only modest efficacy and are associated with resistance and adverse reactions; existing PCSK9 inhibitors are are limited to injectable formulations, which contribute to poor patient compliance, high costs, and suboptimal suitability for long-term management of atherosclerotic cardiovascular disease (ASCVD). S016 is a novel oral small-molecule PCSK9 inhibitor designed to precisely target its intended site and regulate cholesterol clearance pathways. Preclinical studies have demonstrated that S016 exhibits potent lipid-lowering activity and a favorable cardiac safety profile. Its oral route of administration offers a significant convenience advantage over injectable alternatives. By addressing the shortcomings of current therapies, S016 has the potential to fill the clinical gap for an oral PCSK9 inhibitor, providing a new treatment paradigm for patients with hypercholesterolemia and cardiovascular disease. The findings support S016's strong translational potential and its promising outlook for future clinical development and commercial application. Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment. For further details, please visit the official SBK website： https://www.sbkswyy.cn/

近日，第十届斯坦福药物发现研讨会（Stanford Drug Discovery Symposium，SDDS）于美国斯坦福大学成功举办。施贝康受邀参与本次国际会议，与全球医药领域科研学者、产业代表、监管专家等开展深度交流，共同探讨药物研发创新路径与医药产业可持续发展方向。 SDDS 2026：集聚全产业链资源，搭建全球医药核心交流平台 历经十年积淀，SDDS 已成长为全球药物研发领域极具权威性与影响力的学术交流平台。本届盛会整合生物医药全产业优质资源，搭建高效的跨界创新交流平台，覆盖产业全链条： 学术端： 本次会议邀请到6位诺贝尔奖得主及全球顶尖科研学者参会，分享前沿科研成果，指引药物研发前沿方向； 监管端： FDA多位核心监管专家出席会议，共同研讨全球新药审批标准、行业合规体系及相关政策趋势； 产业端： 安进、吉利德、礼来、武田、赛诺菲、百时美施贵宝、拜耳、强生等国际头部药企高管齐聚现场，围绕新药管线布局、核心技术迭代升级等行业核心议题开展交流； 临床端： 斯坦福医学院、美国国立卫生研究院等权威临床科研机构参与研讨，助力打通基础科研与临床转化的衔接通道。 深度参与国际学术研讨，布局医药全球化协同发展 会议期间，施贝康全程深度参与前沿议题研讨，与诺奖得主、FDA监管专家、跨国药企高管、权威医学专家展开面对面交流，对标国际前沿研发理念，分享企业自研技术平台创新成果与核心管线研发进展，积极探索全球学术合作、临床开发、商业化等多元化的国际协同合作模式。 成都施贝康生物医药科技有限公司，成立于2015年，是一家立足中国，面向全球，专注于新药差异化创新的研发性企业。施贝康秉承“施予众生、倍佑安康”的使命，坚持“以‘人’为本，革新为主，创新至上”的价值观。以临床需求为导向，坚持创新驱动发展，重点聚焦心脑血管、呼吸系统等疾病治疗领域，致力于成为全球一流的新药差异化创新的领导者，研发更好的新药，施予众生，加倍呵护人类健康。 详情请访问公司网站： https://www.sbkswyy.cn/ Shibeikang Joins Stanford SDDS 10th Anniversary Symposium to Advance Global Drug Innovation The 10th Annual Stanford Drug Discovery Symposium (SDDS) was recently held at Stanford University in the United States. Shibeikang was invited to this international conference, engaging in in-depth exchanges with academic researchers, industry leaders, and regulatory experts from around the world. The discussions focused on innovative pathways in drug discovery and the long-term sustainable development of the pharmaceutical industry. SDDS 2026: Uniting Global Resources as a Premier Hub for Cross-Sector Collaboration After a decade of development, SDDS has emerged as a highly influential and authoritative platform in the global drug discovery community. This year’s symposium brought together diverse resources across the biomedical value chain to foster efficient cross-sector innovation and collaboration, spanning: Academia: Six Nobel Laureates and leading international researchers shared cutting-edge scientific findings, helping to chart the future direction of drug discovery; Regulation: Key experts from the U.S. Food and Drug Administration (FDA) discussed global standards for new drug approval, industry compliance frameworks, and related policy trends; Industry: Senior executives from global pharmaceutical leaders including Amgen, Gilead, Lilly, Takeda, Sanofi, Bristol-Myers Squibb, Bayer, and Johnson & Johnson convened to address key topics such as pipeline strategy and next-generation technology platforms; Clinical Research: Prestigious institutions including Stanford School of Medicine and the U.S. National Institutes of Health (NIH) participated in discussions aimed at bridging the gap between fundamental research and clinical translation. Deep Engagement in International Scientific Dialogue to Accelerate Global Collaborative Development Throughout the conference, Shibeikang took an active role in forward-looking discussions, engaging directly with Nobel Laureates, FDA regulatory experts, multinational pharma executives, and leading clinicians. The company benchmarked its R&D approaches against global best practices, shared progress on its proprietary technology platforms and core pipeline assets, and actively explored diverse international collaboration models spanning academic partnerships, clinical development, and commercial pathways. Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment. For further details, please visit the official SBK website： https://www.sbkswyy.cn/